Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

6 Feb 2008 07:01

Angle PLC06 February 2008 For Immediate Release 6 February 2008 ANGLE plc ('ANGLE' or the 'Company') ANGLE selected for Long-term Management Contract with London Development Agency Knowledge Connect Programme ANGLE plc (AIM:AGL), the intellectual property and technology commercialisationcompany, announces that it has been selected as a preferred bidder for a majornew management contract worth £3.7 million over the next three years. ANGLE has been selected by the London Development Agency (LDA), subject tocontract, for the delivery of the Knowledge Connect Programme. The KnowledgeConnect Programme aims to increase the level of business research anddevelopment in London by creating new collaborations between business and theLondon knowledge base, with a focus on enterprises that have not previouslyworked with this sector. This flagship Programme, a core part of the LDA's Knowledge Transfer Strategy,will engage with 1,600 businesses and involve ANGLE working intensively with 265businesses across London. The Programme is being established to raise theperformance and aspirations of London's businesses by providing effectivesupport for research and development, knowledge transfer and innovation acrossthe Capital. ANGLE was selected following a competitive tendering process on the basis of itsexperience in delivering similar business support programmes in London, UK wideand internationally. Additionally ANGLE has developed techniques which, it wasable to demonstrate, have secured successful knowledge transfer from academicand research institutions and have measurable business benefits for a wide rangeof small and medium sized enterprises (SMEs). Andrew Newland, Chief Executive of ANGLE, said: "This represents a major success for our Management services business andunderlines our strategy of focusing on long-term and profitable contracts. Inaddition to generating new revenue for ANGLE it also clearly illustrates theattraction of our business model for SMEs looking to develop and commercialisetheir IP. "We are delighted to have been selected to partner the London Development Agencyin this new project. Our team is looking forward to working with London'sbusinesses to help identify new opportunities and secure business growth throughknowledge transfer and innovation." Garth Selvey, Chairman of ANGLE, added: "This project adds to the strength of our Management services business, whichprovides the platform for ANGLE's ongoing operation. As stated in our InterimResults for the six months ended 31 October 2007 released on 31 January 2008,the Board believes that several of ANGLE's portfolio companies have thepotential to deliver substantial cash returns for shareholders." Enquiries:ANGLE plc +44 (0)1483 295830Andrew Newland, Chief ExecutiveIan Griffiths, Finance Director Buchanan Communications +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management company focusingon the commercialisation of technology and the development of technology-basedindustry. ANGLE creates, develops and advises technology businesses on its ownbehalf and for its clients. ANGLE is listed on AIM (AGL.L); further informationcan be found on www.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
25th Jun 20195:19 pmRNSResult of Placing
25th Jun 20198:02 amRNSAccelerated bookbuild to raise £18.0m
21st Jun 20197:00 amRNSParsortix used to investigate immunotherapy target
5th Jun 20197:00 amRNSCompletion of Ovarian Cancer Pre-Study
31st May 20197:00 amRNSPositive Results from FDA Clinical Study
26th Apr 20197:00 amRNSIMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18th Apr 20197:00 amRNSParsortix used in new cancer assessment technique
12th Apr 20197:00 amRNSLUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
4th Apr 20197:00 amRNSAACR 2019
11th Mar 20197:00 amRNSHolding(s) in Company
7th Mar 20197:00 amRNSENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28th Feb 20197:00 amRNSFIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25th Feb 20197:00 amRNSCUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11th Feb 20197:00 amRNSResearch into role of immune cells in cancer
31st Jan 20197:00 amRNSInterim Results
29th Jan 20197:00 amRNSNEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11th Jan 20192:05 pmRNSSecond Price Monitoring Extn
11th Jan 20192:00 pmRNSPrice Monitoring Extension
11th Jan 201911:05 amRNSSecond Price Monitoring Extn
11th Jan 201911:00 amRNSPrice Monitoring Extension
11th Jan 20199:05 amRNSSecond Price Monitoring Extn
11th Jan 20199:00 amRNSPrice Monitoring Extension
10th Jan 20194:41 pmRNSSecond Price Monitoring Extn
10th Jan 20194:36 pmRNSPrice Monitoring Extension
10th Jan 20194:01 pmRNSBREAKTHROUGH CANCER RESEARCH USING PARSORTIX
9th Jan 20197:00 amRNSNotice of Results
21st Dec 20187:00 amRNSIssue of LTIP Options and Share Options
28th Nov 20187:00 amRNSLEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR
13th Nov 20185:10 pmRNSHolding(s) in Company
5th Nov 20187:00 amRNSAcquisition of outstanding shares
2nd Nov 20182:00 pmRNSPrice Monitoring Extension
1st Nov 20187:00 amRNSAppointment of Dr Jan Groen as NED
30th Oct 20184:21 pmRNSResult of AGM
29th Oct 20187:00 amRNSPARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS
25th Oct 20187:00 amRNSGood Progress with FDA Studies
9th Oct 20187:00 amRNSNotice of AGM
28th Aug 20187:00 amRNSParsortix shows evidence of CTCs in glioblastoma
25th Jul 20187:00 amRNSPreliminary Results for year ended 30 April 2018
24th Jul 20185:42 pmRNSEIS/VCT Advance Assurance and Total Voting Rights
18th Jul 201810:34 amRNSResult of General Meeting
2nd Jul 20187:00 amRNSNotice of Preliminary Results
25th Jun 20186:20 pmRNSResults of Fundraising
25th Jun 20182:58 pmRNSClose of Accelerated Bookbuild
25th Jun 20187:50 amRNSProposed Placing of New Ordinary Shares
4th Jun 20187:00 amRNSENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY
14th May 20187:00 amRNSLeading cancer surgeon appointed
3rd May 20187:00 amRNSAngle & QIAGEN Poster
19th Apr 20187:00 amRNSParsortix in multiple presentations at AACR
19th Apr 20187:00 amRNSBreakthrough Research with Parsortix
5th Apr 20187:00 amRNSFirst patient enrolled in FDA study

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.